Cipla Limited (BOM:500087)
India · Delayed Price · Currency is INR | Market Cap | 1.10T -13.8% |
| Revenue (ttm) | 279.89B +0.1% |
| Net Income | 28.97B -46.8% |
| EPS | 35.85 -46.7% |
| Shares Out | n/a |
| PE Ratio | 37.94 |
| Forward PE | 24.62 |
| Dividend | 13.00 (0.96%) |
| Ex-Dividend Date | Jun 5, 2026 |
| Volume | 42,146 |
| Open | 1,335.20 |
| Previous Close | 1,350.00 |
| Day's Range | 1,327.05 - 1,368.00 |
| 52-Week Range | 1,165.55 - 1,598.70 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1,504.81 (+10.65%) |
| Earnings Date | Oct 27, 2026 |
About Cipla
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, ... [Read more]
Financial Performance
In fiscal year 2026, Cipla's revenue was 278.28 billion, an increase of 2.06% compared to the previous year's 272.67 billion. Earnings were 38.79 billion, a decrease of -26.43%.
Financial StatementsAnalyst Summary
According to 36 analysts, the average rating for 500087 stock is "Buy." The 12-month stock price target is ₹1,505, which is an increase of 10.65% from the latest price.
News
Cipla Transcript: Q2 26/27
Q2 revenue reached INR 7,404 crore, with sequential margin expansion and record One India revenue. FY27 U.S. run-rate and EBITDA guidance were maintained, relying on product launches and supply ramp-ups amid regulatory and timing uncertainties.
Cipla Quarterly report: Q2 2027
Cipla has published its Q2 2027 quarterly earnings report on October 27, 2026.
Cipla Slides: Q2 2027
Cipla has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 27, 2026.
India's Cipla misses quarterly profit view on muted US sales
Cipla , India's third-largest drugmaker by revenue, missed second-quarter profit estimates on Tuesday, as muted sales of generic Revlimid and stiff competition weighed on its US business.
Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t
Financial headlines are not typically dominated by Indoco Remedies. Its market capitalization of about ₹2,200 crore keeps it firmly in mid-cap territory, where stocks can move sharply on relatively mo...
FDA cancels Pune Cipla facility's drug sale and distribution licences
Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences of Cipla Pharma's warehouse in Pune. This decision followed an investigation into alleged violations rega...
Cipla's Pune Godown Loses Drug Licence Over 'Misbranding, Storage Violations'
A major reason for the action was the misbranding of 'Reactin Plus', a Schedule-H drug that cannot be sold over the counter.
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
India's Cipla said on Thursday its U.S. unit entered an exclusive partnership with China's Qilu Pharmaceutical to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. market.
‘You’re going overboard’: Bombay high court to FDA, restores Cipla’s licence
Maharashtra FDA withdrew its cancellation of Cipla Pharma's drug sale license after court intervention. The Bombay High Court criticized the regulator for acting high-handedly and violating natural ju...
After Bombay HC rap, FDA withdraws orders against Cipla, MCA eateries
The Bombay High Court took a firm stance against the Maharashtra FDA, rebuking its treatment of Cipla and five eateries. The court underscored that the FDA's decisions compromised natural justice and ...
Maharashtra FDA cancels Cipla unit’s drug sale licences in Pune
Maharashtra FDA cancels Cipla’s Pune C&F unit drug sale licences after Reactin Plus mislabelling and stock, storage and record-keeping irregularities; Cipla contests.
Maharashtra FDA cancels Pune Cipla facility’s sale licences over ‘lapses’
State FDA cancelled Cipla's drug sale licences for its Pune facility. This action followed violations found during an investigation into drug packaging and recall. Officials discovered mislabelling on...
Misbranding, storage lapses: FDA cancels Cipla Pune unit’s drug licence over Reactin Plus violations
The Maharashtra Food and Drug Administration has revoked Cipla's licenses to sell Reactin Plus Tablets due to serious violations in packaging and storage practices. Medicines were improperly stored on...
Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
(RTTNews) - The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant clinical trial ...
Cipla Receives FDA Approval For Generic Advair Diskus In All Strengths
(RTTNews) - Cipla Limited (CIPLA) announced that the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) for the generic version of Advair across all three strengths—100/50 mcg, 250/50 m...
Cipla Transcript: Q1 26/27
Q1 FY27 saw record revenue of INR 7,119 crore, with strong growth in India and North America, driven by chronic therapies and new launches. EBITDA margin was 16.7%, impacted by war-related costs and inventory write-offs. Guidance for FY27 EBITDA margin remains at 18.5%-20%, with U.S. business targeting a $1 billion exit run rate.
Cipla Quarterly report: Q1 2027
Cipla has published its Q1 2027 quarterly earnings report on July 23, 2026.
Cipla Slides: Q1 2027
Cipla has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 23, 2026.
Indian drugmaker Cipla's quarterly profit shrinks more than expected
India's Cipla reported a bigger-than-expected fall in first-quarter profit on Thursday, extending its run of declines on muted sales of a generic cancer drug and supply disruptions tied to tumor treat...
Cipla corrects transcript of 90th AGM due to typographical errors
Cipla Limited has issued a corrigendum to rectify typographical errors found in the transcript of its 90th Annual General Meeting (AGM), initially notified on 3rd July 2026. The corrected transcript…
Cipla holds 90th AGM, highlights 90-year journey and commitment to affordable healthcare
Cipla Limited recently conducted its 90th Annual General Meeting (AGM) on 25th June 2026, via video conferencing. The meeting was attended by key members of the board, including Dr Y…
Cipla's ESG rating revised from 68 to 64 by ESGRisks.ai
Cipla's ESG rating has been revised downward from 68 to 64 by ESG Risk Assessments & Insights Limited (ESGRisks.ai), a SEBI-registered ESG rating provider. The revision follows a re-evaluation based…
Pharma sector stocks trade mixed on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41%
Pharma stocks traded mixed on June 22, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Pharma sector stocks today on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41%
Pharma stocks traded mixed on June 22, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Cipla advertises Reactin Plus, FDA says recall stock in state
Maharashtra FDA issued notice to Cipla Pharma & Life Sciences to recall Schedule H drug Reactin Plus statewide over prohibited advertising; ₹11.19 lakh seized.